What's Happening?
Eli Lilly has entered into a licensing agreement with Hanmi Pharma for sonefpeglutide, a GLP-2 analogue, for multiple gastrointestinal indications. The deal involves an upfront payment of $75 million, with potential additional payments totaling $1.185
billion based on clinical, regulatory, and commercial milestones. Sonefpeglutide is currently in a phase 2 trial in the U.S. for short bowel syndrome (SBS), a condition where patients cannot absorb sufficient nutrients due to a shortened or malfunctioning small intestine. The drug, developed using Hanmi's LAPSCOVERY platform, is designed for once-monthly subcutaneous injection. This agreement is part of Lilly's broader strategy of acquisitions and licensing deals, driven by strong sales of its GLP-1 weight-loss therapies.
Why It's Important?
This licensing deal underscores Eli Lilly's strategic focus on expanding its pipeline in the gastrointestinal sector, particularly in rare conditions like short bowel syndrome. The agreement highlights the potential of sonefpeglutide to address unmet medical needs in SBS, offering a long-acting treatment option that could improve patient outcomes. The deal also reflects the competitive landscape of GLP-2 therapies, with existing treatments like Takeda's Gattex and ongoing developments by other pharmaceutical companies. For Hanmi, this partnership provides significant financial backing and the opportunity to leverage Lilly's global reach to bring sonefpeglutide to a broader market.
What's Next?
Hanmi will continue the phase 2 trial of sonefpeglutide in SBS, with results expected next year. Meanwhile, Eli Lilly plans to explore additional clinical trials based on existing data, potentially expanding the drug's indications. The success of this partnership could lead to further collaborations between the two companies, building on their previous alliance in 2015. The outcome of the ongoing trial and subsequent regulatory approvals will be critical in determining the drug's market entry and its impact on the treatment landscape for gastrointestinal disorders.
